STOCKS TELEGRAPH

Tag: Pieris Pharmaceuticals

  • Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading

    Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading

    Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) shares surged significantly on US stock charts after the announcement of a formal merger agreement. Pre-market activity showed that PIRS stock had increased impressively by 69.27%, to $13.44 per share.

    The Merger Agreement

    Pieris Pharmaceuticals (PIRS) has entered into a definitive merger agreement with Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for rare genetic skin disorders lacking FDA-approved therapies.

    In order to cancel Palvella’s capital stock and make Palvella a wholly-owned subsidiary of Pieris, this strategic merger will comprise an all-stock transaction in which Pieris would issue shares of its common stock to pre-merger Palvella investors.

    Strategic Focus and Future Prospects

    The combined entity will concentrate on advancing and commercializing Palvella’s leading clinical product candidate, QTORIN 3.9% rapamycin anhydrous gel. This therapeutic gel is designed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and other severe skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

    Following the merger, the new business will continue to operate under the name Palvella Therapeutics, Inc.; it will have its headquarters in Wayne, Pennsylvania, and it plans to list on The Nasdaq Capital Market.

    Prospective Development

    This merger underscores Pieris Pharmaceuticals’ commitment to delivering value to its shareholders by preserving the future potential milestone and royalty streams from its partnered immuno-oncology bispecifics franchise through Contingent Value Rights (CVRs) for legacy Pieris stockholders.

    Moreover, it offers the potential for significant growth within a promising, late-stage rare disease company. With anticipated funding and a seasoned management team, the merged company is poised to advance a Phase 3 clinical program, benefiting from the FDA’s Breakthrough, Fast Track, and Orphan Drug Therapy Designations.

    Post-merger, pre-merger Pieris stockholders are projected to hold approximately 18% of the combined company, while pre-merger Palvella stockholders are expected to own around 82%, prior to the issuance of shares under concurrent private financing.

  • How Come Pieris (PIRS) Stock Is Rallying This Morning?

    Shares of Pieris Pharmaceuticals Inc. (PIRS) were up 6.22% in early trading today at $3.76. Pieris Pharmaceuticals dipped 4.12% or $0.14 as shares closed at $3.54 last session. PIRS stock traded between $3.39 and $3.56 during the day. There were 1.84 million shares exchanged, below the company’s average daily volume of 11.94 million.

    The PIRS stock has rallied 8.26% over the past 12 months, and it has increased 2.02% over the last one week. PIRS stock price has increased by 27.34% over the past six months, and by 41.60% over the past three months. With federal authorities giving orphan drug status to one of its drugs, PIRS stock has been rising.

    PIRS has received approval for what?

    Pieris develops medicines utilizing the latest approaches in protein engineering combined with deep expertise in molecular mechanisms behind the disease. The medicines from PIRS produce superior outcomes for patients by driving local biology. Among the pipeline products of PIRS are inhalable Anticalin proteins to treat respiratory disorders and locally-activated bispecifics to target immune-related diseases. Anticalin proteins, the proprietary property of PIRS, are a class of therapeutics that have been validated clinically and through partnerships with leading pharmaceutical companies.

    Cinrebafusp alfa (PRS-343) received the medical designation of an orphan drug from the US Food and Drug Administration (FDA), announced Pieris.

    • This bispecific treatment will target both gastric cancers with HER2-high and HER2-low expression.
    • It is poignant that PIRS cinrebafusp alfa has been granted orphan drug designation because of the significant unmet medical needs associated with gastric cancer.
    • Furthermore, the study reaffirms PIRS’ conviction that the program needs to be implemented while setting high success goals to help patients with limited options in treatment.
    • Later this summer, PIRS plans to begin the second phase of the cinrebafusp alfa trial.
    • FDA grants orphan drug designation to drugs that target conditions that affect 200,000 or fewer US patients each year.
    • Cinrebafusp alfa’s Orphan Drug Designation will provide development as well as commercial incentives to PIRS.
    • PIRS will enjoy assistance from FDA for the design of clinical trials, tax credits for qualified clinical trials as well as waivers of application fees as part of this designation.
    • Additionally, it will grant PIRS a seven-year market exclusivity following FDA approval for the development and commercialization of cinrebafusp alfa.

    PIRS’ further plans:

    Pieris (PIRS) is actively pursuing a phase 2 study of cinrebafusp alfa following the positive phase 1 results, which indicate that the therapy is a single agent with a mechanism of action related to 4-1BB. For that phase, PIRS will combine cinrebafusp alfa with ramucirumab and paclitaxel for treating HER2-high expression gastric cancer and tucatinib for treating HER2-low expression gastric cancer.

  • Pieris Pharmaceuticals Inc. (PIRS) stock has soared in the current session; Here’s why this is happening

    Pieris Pharmaceuticals Inc. (PIRS) stock has soared in the current session; Here’s why this is happening

    Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) stock last closed at $2.50. The PIRS stock is currently trading at $2.52 and is up by 0.40% at this time of writing.

    The current positive trend in the PIRS stock movement comes after the announcement by the clinical-stage biotechnology company of amendment in its collaboration with Seagen.

    The biotech company’s specific clinical-trial focus

    Pieris is a biotech company that specifically focuses its clinical-trial experiments on Anticalin protein-based drugs. The clinical stage company focuses on the developing and discovering of Anticalinto focus on targeting validated disease pathways in a way that is efficiently impactful. The company’s future and current treatment projects consist of respiratory diseases and immune-oncology multi-specifics associated with tumor.

    How does the amendment in agreement specifically change the collaboration?

    The amendment in the collaboration with Seagen in detail specifies Seagen’s strategic equity investment. This amendment in detail switches the option of development, promotion and commercialization rights of the existing immune-oncology agreement for the second of up to three products in the alliance. This investment has a purchasing price of $13 million in PIRS common stock. Total amount of stocks correlated to this investment will consist of 3,706,174 shares at the price of $3.51 per share.

    Furthermore the contractual reinstatements allow Pieris’ collaboration co-promotion option instead of co-development and co-commercialization of the project. At the same time, Seagen will solely be responsible for the development and commercialization of the project. Pieris can also increase its royalty if it chooses to implement this option.

    Both companies have also entered into a clinical trial collaboration agreement that will determine the efficacy of combining cinrebafuspalfa (PRS-343) with TUKYSA. PRS-343 is a 4-1BB/HER2 bispecific experiment of Pieris with Seagen’stucanib which is a small-molecule tyrosine kinase HER2 inhibitor. Both HER2 inhibitors are to be combined to test the treatment of gastric cancer patients that are depicting low HER2 levels. The safety of this test is also to be evaluated as part of Pieris’s upcoming phase 2 studies.

    The significance of this collaboration

    The significance of this combination of HER2 inhibitors is that it can address uniquely and specifically the patients with HER2 low expressing gastric cancer who do not respond to HER2-targeted therapies. Pieris lives up to its aim of combing and developing unique and innovative treatments for immune-oncology and respiratory diseases. In past, the PIRS stock went up due to similar collaboration and partnership announcements on projects with AstraZeneca, Servier and Seagen.